NFE2L2 and amyotrophic lateral sclerosis: The future trajectory of Nrf2-based therapeutics will likely require combinatorial strategies integrating pharmacological activators, gene therapies, and ASOs, tailored to specific ALS subtypes and progression phenotypes.